R&D JP Morgan Week 2025 - Day 3 pharmaphorum's JPM Week live blog finishes strong with panels on AI, funding, and a conference wrap-up.
R&D JP Morgan Week 2025 - Day 2 On day 2 of pharmaphorum's JPM Week blog, we'll hear from leaders from the President of Novartis, a stacked industry panel on AI, and Dr Jill Biden.
News Lilly nets Scorpion cancer drug in $2.5bn licensing deal Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
R&D JP Morgan Week 2025 - Day 1 On day 1 of JPM Week, join pharmaphorum as we hear about pharma's dealmaking plans and the changing pharma landscape.
News J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
